Home
ENGN
ENGN News

Latest enGene Holdings Inc. (ENGN) News on November 15, 2025

MT Newswires

2 days ago

EnGene Prices $130 Million Offering of Common Shares, Warrants

enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results

Simply Wall St.

2 days ago

enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Business Wire

2 days ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

MT Newswires

2 days ago

EnGene Launches Offering of Common Shares

enGene Announces Proposed Public Offering of Common Shares

Business Wire

3 days ago

enGene Announces Proposed Public Offering of Common Shares

MT Newswires

3 days ago

Oppenheimer Adjusts Price Target on enGene Holdings to $33 From $30, Maintains Outperform Rating

MT Newswires

3 days ago

UBS Boosts Price Target on enGene Holdings to $10 From $4, Keeps Neutral Rating

enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial

Clinical Trials Arena

4 days ago

enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial

MT Newswires

4 days ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires

4 days ago

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Investors Assess Impact of Government Shutdown

MT Newswires

4 days ago

EnGene's Mid-Stage Trial Shows Improved Complete Response Rate in Non-Muscle Invasive Bladder Cancer Patients

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Business Wire

4 days ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Business Wire

5 days ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

enGene to Participate in Upcoming Investor Conferences

Business Wire

8 days ago

enGene to Participate in Upcoming Investor Conferences

enGene Named a BioSpace 2026 Best Places to Work Winner

Business Wire

11 days ago

enGene Named a BioSpace 2026 Best Places to Work Winner

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a month ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire

2 months ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

MT Newswires

5 months ago

enGene Receives RMAT Designation From US FDA for Bladder Cancer Therapy

FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Business Wire

5 months ago

FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

5 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Business Wire

5 months ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Announces the Resignation of its Chief Medical Officer

Business Wire

5 months ago

enGene Announces the Resignation of its Chief Medical Officer

enGene to Present at the Jefferies Global Healthcare Conference

Business Wire

6 months ago

enGene to Present at the Jefferies Global Healthcare Conference

enGene Names Amy Pott as Chief Global Commercialization Officer

Business Wire

6 months ago

enGene Names Amy Pott as Chief Global Commercialization Officer

enGene to Participate in Upcoming Investor Conferences

Business Wire

7 months ago

enGene to Participate in Upcoming Investor Conferences

enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35%

Simply Wall St.

7 months ago

enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35%

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

7 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Business Wire

7 months ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Holdings Insider Ups Holding During Year

Simply Wall St.

8 months ago

enGene Holdings Insider Ups Holding During Year

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire

8 months ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

Business Wire

8 months ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire

9 months ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

9 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Business Wire

10 months ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a year ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/27/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/26/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/24/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/23/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/20/2024

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Business Wire

a year ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/19/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/18/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/17/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/16/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/13/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/12/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/11/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/10/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/09/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/06/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/05/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/04/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/03/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 12/02/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/29/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/27/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/26/2024

enGene to Participate in Upcoming Investor Conferences

Business Wire

a year ago

enGene to Participate in Upcoming Investor Conferences

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/25/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/22/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/21/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/20/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/19/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/18/2024

With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners

Simply Wall St.

a year ago

With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/15/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/14/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/13/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/08/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/07/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/06/2024

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

Business Wire

a year ago

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/05/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/04/2024

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 11/04/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/31/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/30/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/29/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/28/2024

enGene Announces $60 Million Private Placement Financing

Business Wire

a year ago

enGene Announces $60 Million Private Placement Financing

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/25/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/24/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/23/2024

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/22/2024

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Business Wire

a year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/21/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 10/21/2024

Insider Buys Additional US$57k In enGene Holdings Stock

Simply Wall St.

a year ago

Insider Buys Additional US$57k In enGene Holdings Stock

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a year ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Business Wire

a year ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire

a year ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

Business Wire

a year ago

enGene to Participate in Upcoming Investor Conferences

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a year ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Business Wire

a year ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Business Wire

a year ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Share on Social Networks: